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ter the threshold for optimal cytoreduction has been reached, it is important to remove as much of the residual tumor as possible [5] .
Circulation of peritoneal fluid throughout the abdomen and pelvis commonly results in diaphragmatic tumor implants, and in turn, peritonealpleural communication through the diaphragm may allow transdiaphragmatic spread of tumor into the tho rax [6] . Malignant thoracic involvement indicates FIGO stage IV disease, for which treatment options include neoadjuvant chemotherapy and, in patients who are candidates for optimal abdominal cytoreduction, thoracic debulking [7, 8] . Neoadju vant chemotherapy followed by interval debulking surgery is a suitable alternative [9, 10] that is supported by the outcome of a recent multicentre randomised controlled trial [11] .
Several studies have demonstrated that the thorax frequently harbors undiagnosed pleural disease at the time of the initial diagnosis, and that this is likely to affect survival even in cases of optimal debulking [1214] . In addition, a recent study found that moderatetolarge pleural effusion on preoperative com puted tomography (CT) was associated with a decrease in overall survival in patients with stage III or IV EOC after control ling for age, preoperative CA125, surgical stage, ascites, and cytoreductive status [15] . Therefore, accurate identification of the presence and extent of thoracic disease, including both solid metastasis and malignant pleural effusion, is important for determining prognosis and selecting appropriate treat 262 www.ejgo.org ment in patients with advanced EOC [15] (Figs. 1 and 2 ).
Pleural effusions in ovarian cancer have a higher likelihood of malignancy when they are moderate to large in size and as sociated with enlarged superior diaphragmatic lymph nodes [6] . However, studies on CT indicators of malignant pleural effusion have used cytology rather than surgical findings as the reference standard [6, 16, 17] . The accuracy of pleural fluid cytologic examination ranges between 40% and 87% [18 20] . Videoassisted thoracic surgery (VATS) has been shown to enable accurate pathological diagnosis and intrathoracic resection of pleural metastasis in patients with ovarian cancer [21] . In a small retrospective study from our institution, 4/10 patients (40%) with negative cytological findings had macro scopic pleural lesions on VATS [13] , and in another such study, preoperative CT identified solid pleural disease in only one third of patients (2/6) who had macroscopic disease on VATS [14] . Therefore, the aims of our study were to compare chest CT to VATS, pathology, and cytology findings and determine possible CT imaging features that may be predictive of pleural malignancy in patients with advanced EOC.
MATERIALS AND METHODS

Patients
Our retrospective, crosssectional imaging study was com pliant with Health Insurance Portability and Accountability Act. The institutional review board approved the study and is sued a waiver of informed consent. Patients were selected by means of a computerized review of institutional gynecologic surgery and radiology databases. Consecutive patients with primary or recurrent FIGO stage III and IV ovarian cancer who underwent CT of the chest up to 30 days before VATS from January 1, 1997 through December 31, 2009 were included in the study. If a patient had more than one CT study within the 30 days before VATS, the most recent one was used. A total of 44 patients (3 with FIGO stage III and 41 with FIGO stage IV) were included in the analysis, of whom 41 had primary and 3 had recurrent disease. Indications for VATS were malignant pleural effusion on cytology (12/44), suspected malignant nodules or lymph nodes on CT (16/44) or moderate to large (defined as occupying 1/3 or more of the lung field on chest Xray) and/or recurrent pleural effusions (16/44).
CT examinations
Most of the CT examinations (32/44) were performed with intravenous contrast medium, and the slice thickness ranged from 5 to 8 mm. For CT examinations performed outside our institution, the type of CT scanner and the amount of con trast material used were unknown. At our institution, CT was performed with various scanners (GE Medical Systems, Mil waukee, WI, USA). Our standard CT protocols were tailored to the individual scanners. Before October 1, 2000, studies were obtained with a conventional nonhelical scanner; afterwards they were obtained with a helical scanner with one to 64 de tector rows.
For all CT examinations performed at our institution, a dy namic power injection of 150 mL of nonionic intravenous 
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contrast material was administered at a rate of 2.5 mL/second. Time delay to scanning varied with the type of scanner used but was determined on the basis of the typical time to portal venous phase imaging. All CT studies that were done outside our institution were digitized and sent to our enterprisewide picture archiving and communication system.
Image analysis
Images were retrospectively and independently analyzed by two radiologists (SM and ES) who were aware that the patients had ovarian cancer but were blinded to the patients' clinical data, prospective CT reports, and pathology findings. Both readers were fellowshiptrained in body imaging with 8 years of experience in oncologic imaging.
For each patient, the radiologists recorded the presence and size of pleural effusion. Pleural effusion size was categorized based on visual estimation as small (occupying less than 1/3 of the visualized hemithorax), moderate (1/3 to 2/3 of the hemithorax), or large (more than 2/3 of the hemithorax). Pre vious work has suggested visual approximation to be about 85% accurate compared to 3D CT reconstruction [22] . The radiologists recorded the presence of pleural nodules, pleural thickening (greater than 3 mm), pleural enhancement and subdiaphragmatic deposits. They also noted the presence of supradiaphragmatic (greater than 5 mm), mediastinal, hilar, and retroperitoneal lymphadenopathy. In addition, they esti mated the size of ascites and recorded the presence of perito neal seeding if present.
Reference standard
Results from VATS served as the reference standard. All pro cedures were performed at our institution by gynecologic oncology and thoracic surgical teams whose members' expe rience ranged from 5 to 25 years. VATS was performed based on CT findings. Rightsided VATS was performed in 27 of the 44 patients, leftsided VATS in 8 and bilateral in 9. The proce dure included supradiaphragmatic lymph node dissection if indicated (in 12 patients), drainage of effusion (in 35 patients), and pleural biopsy of any suspicious areas or of random areas if no suspicious areas were identified. A research study assis tant (OM) reviewed the intraoperative notes and pathology reports retrospectively to determine whether any effusion was drained preoperatively or intraoperatively and to record cyto pathological and histopathological results (for 9 patients, cy tology results were not available either because there was no effusion or because macroscopic pleural disease was present and thus cytologic evaluation was not completed, as it would not have been clinically relevant).
Statistical analyses
Differences in age were compared using the Wilcoxon rank sum test. Differences in imaging features between benign and malignant findings at cytopathology or histopathology were evaluated using Fisher's exact test and Spearman's rank cor relation. Kappa statistics along with 95% confidence intervals were calculated to assess interreader agreement and were interpreted as follows: к<0.00, no agreement; 0.00≤к≤0.20, slight agreement; 0.21≤к≤0.40, fair agreement; 0.41≤к≤0.60, moderate agreement; 0.61≤к≤0.80, substantial agreement; and 0.81≤к≤1.0, almost perfect agreement. All pvalues less than 0.05 were considered statistically significant. All statisti cal analyses were performed by using commercially available software (SPSS ver. 16.0, SPSS Inc, Chicago, IL, USA; SAS ver. 9.0, SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
The patients' median age was 56 years (range, 40 to 81 years). The median time from CT to surgery was 7 days (range, 2 to 30 days). Age did not differ significantly between patients with and without solid pleural metastasis (p=0.66) or be tween patients with and without malignant pleural effusions (p=0.16).
Predicting pleural malignancy
In 26/44 patients (59%), pleural biopsies were positive for malignancy. For both readers, the size of leftsided pleural ef fusion (rho=-0.39, p=0.01 and rho=-0.37, p=0.01 for readers 1 and 2, respectively) and the presence of ascites (rho=-0.33, p=0.03 and rho=-0.35, p=0.03 for readers 1 and 2, respec tively) were the only imaging features associated with malig nant pleural involvement on CT, there was no difference in the presence of pleural nodules, pleural enhancement, pleural thickening, subdiaphragmatic deposits, supradiaphragmatic lymphadenopathy, mediastinal lymphadenopathy, retroperi toneal lymphadenopathy, hilar lymphadenopathy, supracla vicular lymphadenopathy or the presence of peritoneal seed ing between patients with and without pleural malignancy at biopsy (Tables 1 and 2 ).
In 26 (74%) of the 35 patients who had pleural fluid cytology available, the results indicated malignant pleural effusion. The only features associated with malignant pleural effusion were the presence (p=0.03 for both readers) and size (rho=0.34, p=0.04 and rho=0.33, p=0.06 for readers 1 and 2, respectively) of any rightsided pleural effusion (Tables 1 and 2 266 www.ejgo.org 0.61 for agreement on pleural enhancement. Agreement on the amount of ascites was fair (κ=0.37).
DISCUSSION
The management of patients with malignant pleural effu sions and/or intrathoracic metastasis from primary or recurrent advanced EOC is not standardized. The Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference statement, 2004 [23] and the evidence from randomized controlled tri als [11, 24] indicate that disease outside the peritoneum pre cludes optimal debulking and therefore these patients should undergo neoadjuvant chemotherapy followed by cytoreduc tive surgery. Still other studies have reported that patients with malignant pleural effusions as the only extraperitoneal manifestation of the disease have a more favorable prognosis than patients with other sites of stage IV disease such as liver or distant lymph nodes [2527] . A study from our institution in patients who had optimal cytoreduction showed a worse prognosis for those with than for those without malignant pleural effusions [12] . Therefore, it is important for patients with pleural effusions to be appropriately triaged for intratho racic cytoreduction or neoadjuvant chemotherapy depending on the feasibility of optimal cytoreduction [13, 14, 2830] .
In a very recent study of 203 patients with FIGO stage III and IV EOC who underwent CT before primary cytoreductive surgery at our institution, the presence of moderatetolarge pleural effusion on preoperative CT was independently associ ated with poorer overall survival (reader 1: hazard ratio [HR], 2.26, 95% confidence interval [CI], 1.31 to 3.91, p<0.01; reader 2: HR, 2.25, 95% CI, 1.26 to 4.01, p=0.02) after controlling for age, preoperative CA125, surgical stage, ascites and cytore ductive status. Since many patients who had pleural effusions did not have the pleural fluid removed and evaluated for ma lignant cells, it was unclear if the poor prognosis associated with moderatetolarge pleural effusions was due to the size of the effusions, the likelihood that they were malignant, the possibility that they were associated with bulky intrathoracic disease, or a combination of the above. We have previously reported that as many as twothirds of patients with pleural effusions have gross intrathoracic disease on VATS [14] . There fore, at our institution VATS is now routinely performed in pa tients with moderatetolarge pleural effusions.
In our present study the size of pleural effusion and the presence of ascites on CT were associated with malignant pleural effusion. However, CT features generally considered suggestive of solid pleural malignancy such as solid pleural nodules, pleural thickening and enhancement were not asso ciated with pleural malignancy at biopsy or cytology obtained during VATS. Our results agree with those of a prior study of 15 patients with advanced ovarian cancer, in which video assisted thoracoscopy was done to evaluate unilateral or bi lateral pleural effusions or (in one patient) to assess the effects of neoadjuvant chemotherapy on pleural metastases [31] . The study found that preoperative CT had sensitivity of just 14% and specificity of only 25% for determining pleural status when videoassisted thoracoscopy was used as the reference standard [31] .
Several studies have investigated the use of positron emis sion tomography (PET) or PET/CT as an alternative imaging test for diagnosing pleural metastases in patients with me sothelioma and nonsmallcell lung cancer; using pathology from VATS or cytology obtained from thoracocentesis as the reference standard. They found very high accuracy ranging from 92% to 97.5% [3224] . In the primary staging of ovarian cancer, Kitajima et al. [35] found that integrated FDGPET/con trastenhanced CT was more accurate than CT alone. The in cremental value of PET/CT in perlesion accuracy was greater in extrapelvic sites, particularly metastatic lymph nodes in the abdomen; however, almost all patients (39/40) in the study had stage III disease [35] . Further studies are needed to assess the potential of PET/CT for evaluating thoracic metastases from ovarian cancer.
Our study had a number of limitations. First, selection bias may have affected our results, since patients had VATS be cause of suspicion of pleural malignancy based either on CT findings or pleural cytology. Optimally, the same study could be repeated with patients who routinely undergo VATS re gardless of CT findings. Second, we chose an arbitrary period of ≤ 30 days between imaging and surgery. However, we re viewed only the most recent imaging study for each patient so the interval between CT examination and surgery would be as short as possible and the analysis of the relationship between CT and surgical findings would be valid. Third, we combined patients with stage III, stage IV, recurrent disease and different histological subtypes. Subgroup analysis was not feasible given the limited number of patients who under went VATS. Finally, although the size and laterality of pleural effusion are unlikely to be affected by scanning technique or equipment, we cannot account for the variations in CT tech nique and equipment that occurred during the large time span of this study. Detection of pleural metastasis could have been difficult on digitized images from other institutions, and this could account for the fact that interreader agreement was lower for the presence of solid pleural disease (κ=0.46) than for the size of pleural effusion (κ=0.78). Since a number of the CT examinations were performed at outside institutions www.ejgo.org 267 it was not possible to apply a computerassisted method of effusion volume estimation, which may be more accurate than the visual method that was used in our study. Our study also had some important advantages compared to other published studies. First, to our knowledge, our sample size was larger than that of any other published study comparing VATS and CT findings of pleural disease in patients with advanced primary or recurrent EOC. Second, we relied on independent CT readings by two radiologists with substantial experience in oncologic imaging rather than consensus evalu ation of CT images.
In conclusion, we found that in patients with advanced or re current epithelial ovarian cancer, CT imaging findings gen erally considered suggestive of malignant pleural involvement such as nodularity, thickening and enhancement of the pleura do not predict the presence of pleural malignancy on VATS. Therefore, VATS should be considered to evaluate thoracic in volvement in ovarian cancer and facilitate appropriate mana ge ment.
